NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Atterx Biotherapeutics

Atterx Biotherapeutics

Private
Traverse City, MichiganHealthcare & Life Scienceshttps://www.atterx.com/

Last Round

Convertible Debt

Mar 31, 2025

Total Funding Raised

$12.98M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Atterx Biotherapeutics is a biotechnology company that develops novel therapies to combat multi-drug resistant bacterial infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antimicrobial resistancebacterial interferencesuperbugcatheter-associated urinary tract infectionsCAUTIGram-negative bacteriaanti-infectivebiotechdrug discoveryFDA Fast Trackbacterial conjugationclinical-stage biotechpharma licensingantibiotic alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atterx Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Atterx Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Atterx Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMar 31, 2025
Early FundingJan 13, 2023
Series C ExtensionJun 1, 2022
VC RoundApr 25, 2016
Series BMay 14, 2010
Grant
Oct 24, 2008

Key People

Founding team and executive leadership

James Millar

Chief Executive Officer

Executive Team

Atterx Biotherapeutics Investors

Notable investors and investment history

Atterx Biotherapeutics investors
InvestorRounds
Boomerang CatapultSeries C Extension, Early Funding
Northern Michigan AngelsEarly Funding
U.S. Department of WarGrant
Michigan RiseEarly Funding
Michigan Strategic FundEarly Funding, Convertible Debt
Wisconsin Investment PartnersSeries B, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Monthly visitors grew 39% MoM, reaching 1.2K.

  • May 21, 2026

    Monthly visitors increased 45% MoM.

Atterx Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atterx Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atterx Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTraverse City, Michigan
Employee Range3
Year Founded2001
Last FundingMar 31, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.